BERWYN, PA — Mural Health announced it has expanded global payment capabilities within its Mural Link participant management ...

We are pleased to present additional data that further underscore the wide-ranging therapeutic potential of rinvatercept,” said Jasbir S. Seehra, President and Chief Executive Officer of Keros. “These ...

"Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year defined by three pillars of value creation: data on tau-targeting assets for Alzheimer’s disease, clinical entry ...

The Minns Labor Government is providing a funding boost to an Australian-first alliance that's fast-tracking cancer patients across NSW onto ...

Discover why biomarkers are critical in modern drug discovery and clinical trials, enabling better target validation.

Understood reports GLP-1 drugs like Ozempic may improve ADHD symptoms by quieting food thoughts, but more research is needed for direct effects.

A $2.5 billion valuation in biotech isn’t just about current sales; it’s heavily weighted towards future potential, clinical ...

While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...

Abrocitinib shows sustained improvement in atopic dermatitis symptoms over two years with an acceptable safety profile.

Smoking is often assumed to accelerate aging by releasing tissue-damaging molecules called free radicals,” Dr. James T. Handa ...